Loading...
Potential of liraglutide in the treatment of patients with type 2 diabetes
Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds non-covalently to albumin, giving it a pharmacokinetic profile suitable for once-daily administration. In c...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2672437/ https://ncbi.nlm.nih.gov/pubmed/19436648 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|